Dr. Jiajun Fan works as a research associate professor in Department of BiologicalMedicines, School of Pharmacy, Fudan University. He has won 3 National Grantsin the field of scientific and medical research, and his main work is focused on the discovery of novelimmunotherapeutics. His colleagues and he have now established a platform for traditional,ScFv and VHH antibody development. Based on this platform, servalnovel antibodies or fusion proteins have been generated, including anti-ANGPTL3VHH antibody, Anti-VEGF-B full antibody, Anti-CD47 fusion protein,etc. Besides, Dr. Fan is also interested in the mechanism of the occurrence ofthe disease. His group has illustrated how the CD47, an immune checkpoint ofmacrophage, works as a main regulatory factor of microenvironment in a varietyof diseases such as cancer and atherosclerosis, which causes immunosuppressionand therapy resistance.
Immunotherapy,Biotechnology, Antibody Discovery, Cancer, Atherosclerosis
Education
2004.09 ~ 2008.07 Biotechnology, Tongji University, Bachelor.
2009.09 ~ 2012.07 Biochemistry and Molecular Biology, Tongji University, Master
2012.09 ~ 2016.07 Biosynthesis, Fudan University, Ph.D.
Professional Experiences
2016.11 ~ 2019.06 Department of Microbiological and Biochemical Pharmacy, School of Pharmacy, Fudan University, Postdoc.
2019.07 ~ present Department of Biological Medicines, School of Pharmacy, Fudan University, Research Associate Professor.
2019.09 ~ present Fudan Zhang Jiang Institute, Research Associate Professor
2019.11 ~ present Shanghai Engineering Research Center of Immunotherapeutics, Fudan University, Secretary
Grants & Projects
1. China Postdoctoral Science Foundation (No. 2017M611462)
2. China Postdoctoral Science Foundation (No. 2018T110352)
3. National Natural Science Foundation of China (81803529)
Awards & Honors
1. National Scholarship at 2013
2. National Scholarship at 2014
3. Baosteel Scholarship for outstanding students at 2015
4. 2nd Prize Scholarship of Fudan University at 2015
5. Travel award fellow of Japanese Society of Medical Oncology 2015 Annual Meeting
Memberships
2020.03 ~ present Reviewing Editor, Section of Cancer Immunotherapy, Frontiers in Immunology
2020.03 ~ present Reviewing Editor, Section of Cancer Immunotherapy, Frontiers in Oncology
Selected Publications
1. Fan J, Zhang X, Wang S, Chen W, Li Y, Zeng X, Wang Y, Luan J, Li L, Wang Z, Sun X, Shen B, Ju D. Regulating autophagy facilitated therapeutic efficacy of the sonic Hedgehog pathway inhibition on lung adenocarcinoma through GLI2 suppression and ROS production. Cell Death Dis. 2019;10: 626.
2. Fan J, Wang S, Zhang X, Chen W, Li Y, Yang P, Cao Z, Wang Y, Lu W, Ju D. Quantum Dots elicited Hepatotoxicity through Lysosome-dependent Autophagy Activation and ROS Production. ACS Biomater. Sci. Eng. 2018; 4: 1418-1427
3. Fan J, Sun Y, Wang S, Li Y, Zeng X, Cao Z, Yang P, Song P, Wang Z, Xian Z, Gao H, Chen Q, Cui D, Ju D. Inhibition of Autophagy Overcomes the Nanotoxicity Elicited by Cadmium-based Quantum Dots. Biomaterials 2016; 78: 102-14.
4. Fan J, Zeng X, Li Y, Wang S, Wang Z, Yang P, Cao Z, Song P, Chen Q, Wang Y, Luan J, Ju D. A novel therapeutic approach against B-cell non-Hodgkin’s lymphoma through co-inhibition of Hedgehog signaling pathway and autophagy. Tumor Biol. 2016; 37: 7305-14.
5. Fan J, Dong X, Zhang W, Zeng X, Li Y, Sun Y, Wang S, Wang Z, Gao H, Zhao W, Ju D. Tyrosine kinase inhibitor Thiotanib targets Bcr-Abl and induces apoptosis and autophagy in human chronic myeloid leukemia cells. Appl Microbiol Biotechnol. 2014; 98: 9763-75.
6. Fan J, Zeng X, Li Y, Wang S, Wang Z, Sun Y, Gao H, Zhang G, Feng M, Ju D. Autophagy Plays a Critical Role in ChLym-1-Induced Cytotoxicity of Non-Hodgkin's Lymphoma Cells. PLoS One 2013; 8:e72478.
7. Liu P, Fan J, Wang Z, Zai W, Song P, Li Y, Ju D. The role of autophagy in the cytotoxicity induced by trastuzumab emtansine (T?DM1) in HER2?positive breast cancer cells. AMB Express. 2020;10:107. Co-First Author
8. Wang S, Fan J, Mei X, Luan J, Li Y, Zhang X, Chen W, Wang Y, Meng G, Ju D. Interleukin-22 Attenuated Renal Tubular Injury in Aristolochic Acid Nephropathy via Suppressing Activation of NLRP3 Inflammasome. Front Immunol. 2019;10:2277. Co-First Author
9. Zhang X, Chen W, Fan J, Wang S, Xian Z, Luan J, Li Y, Wang Y, Nan Y, Luo M, Li S, Tian W, Ju D. Disrupting CD47-SIRPα axis alone or combined with autophagy depletion for the therapy of glioblastoma. Carcinogenesis. 2018; 39: 689-699. Co-First Author
10. Zhang X, Fan J, Wang S, Li Y, Wang Y, Tian W, Song L, Luan J, Wang Z, Song P, Chen Q, Ju D. Targeting CD47 and autophagy elicited enhanced anti-tumor effects in non-small cell lung cancer. Cancer Immunol Res. 2017;5:363-375. Co-First Author
11. Chen W, Zhang X, Fan J, Zai W, Luan J, Li Y, Wang S, Chen Q, Wang Y, Liang Y, Ju D. Tethering Interleukin-22 to apolipoprotein A-I ameliorates mice from acetaminophen-induced liver injury. Theranostics. 2017;7: 4135-4148. Co-First Author
12. Jiang S, Fan J, Wang Q, Ju D, Feng M, Guan Z, An D, Ye L. Diosgenin induces ROS-dependent autophagy and cytotoxicity via mTOR signaling pathway in chronic myeloid leukemia cells. Phytomedicine. 2016; 23: 243-52. Co-first Author
13. Zhang B, Fan J, Zhang X, Cao Z, Yang P, Shen W, Xu Z, Ju D. Targeting asparagine and autophagy for pulmonary adenocarcinoma therapy. Appl Microbiol Biotechnol. 2016;100: 9145-9161. Co-first Author
14. Ye L, Fan J, Shi X, Tao Q, Ye D, Xian Z, Zeng X, Li Y, Feng M, Ju D. Tumor necrosis therapy antibody interleukin-2 fusion protein elicits prolonged and targeted antitumor effects in vivo. Appl Microbiol Biotechnol. 2014; 98:4053-61. Co-first Author
